The ability of high dose rosuvastatin to improve plaque composition in non-intervened coronary arteries: rationale and design of the Integrated Biomarker and Imaging Study-3 (IBIS-3)

• Published in: EuroIntervention Vol. 8; no. 2; pp. 235 - 241
• Main Authors: SIMSEK, Cihan, GARCIA-GARCIA, Hector M, RAICHLEN, Joel, DUCKERS, Henricus J, ZIJLSTRA, Felix, DER STEEN, Ton Van, BOERSMA, Eric, SERRUYS, Patrick W, GEUNS, Robert-Jan Van, MAGRO, Michael, GIRASIS, Chrysafios, MIEGHEM, Nicolas Van, LENZEN, Mattie, DE BOER, Sanneke, REGAR, Evelyn, DER GIESSEN, Willem Van
• Format: Journal Article
• Language: English
• Published: Toulouse Société Europa Edition 01.06.2012
• Subjects: Biological and medical sciences; Biomarkers; Coronary Artery Disease - drug therapy; Diseases of the cardiovascular system; Fluorobenzenes - adverse effects; Fluorobenzenes - therapeutic use; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Medical sciences; Plaque, Atherosclerotic - drug therapy; Prospective Studies; Pyrimidines - adverse effects; Pyrimidines - therapeutic use; Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects); Research Design; Rosuvastatin Calcium; Spectroscopy, Near-Infrared; Sulfonamides - adverse effects; Sulfonamides - therapeutic use; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases; Ultrasonography, Interventional; near-infrared spectroscopy; Angioplasty; Biological marker; Rosuvastatin; Hypocholesterolemic agent; Stent; Percutaneous route; Design; Near infrared spectrometry; percutaneous coronary intervention; HMG-CoA reductase inhibitor; High dose; Ultrasound; Sonography; Atherectomy; Composition; Enzyme; Coronary artery; Enzyme inhibitor; Instrumentation therapy; Statin derivative; Histology; Hydroxymethylglutaryl-CoA reductase; Medical imagery; Oxidoreductases; intravascular ultrasound-virtual histology; Antilipemic agent
• ISSN: 1774-024X; 1969-6213
• DOI: 10.4244/eijv8i2a37

Acute coronary syndromes (ACS) are often caused by rupture of non-flow limiting "vulnerable" atherosclerotic plaque, characterised by a large necrotic core pool and a thin, inflamed fibrous cap that are unidentifiable with diagnostic coronary angiography. The implementation of novel invasive imaging modalities, such as intravascular ultrasound-virtual histology (IVUS-VH) and near-infrared spectroscopy (NIRS), could help identify high-risk patients who are in need of aggressive medical therapy. The intake of high dose rosuvastatin has been shown to reduce plaque containing necrotic core in the carotid arteries, however it remains unknown whether there is a similar effect in the coronary arteries. The IBIS-3 study is a single centre, non-randomised study designed to evaluate the ability of 12-months high dose rosuvastatin treatment (40 mg daily po) to reduce the necrotic core of a non-intervened coronary segment assessed with IVUS-VH. All patients undergoing diagnostic angiography or percutaneous coronary intervention (PCI) are eligible for participation. Recruitment started in early 2010 and will continue until 350 patients are included. The effect on the lipid core containing plaque will be assessed with near-infrared spectroscopy (NIRS) at 12-months. In addition, multiple biomarkers will be measured and their levels correlated with the imaging results. IBIS-3 will assess the efficacy of high dose rosuvastatin to reduce the necrotic core in a coronary segment of patients who have undergone diagnostic angiography or PCI.